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Background: Small clinical trials are necessary when there are difficulties in recruiting enough patients for
conventional frequentist statistical analyses to provide an appropriate answer. These trials are often necessary for
the study of rare diseases as well as specific study populations e.g. children. It has been estimated that there are
between 6,000 and 8,000 rare diseases that cover a broad range of diseases and patients. In the European Union
these diseases affect up to 30 million people, with about 50% of those affected being children. Therapies for
treating these rare diseases need their efficacy and safety evaluated but due to the small number of potential trial
participants, a standard randomised controlled trial is often not feasible. There are a number of alternative trial
designs to the usual parallel group design, each of which offers specific advantages, but they also have specific
limitations. Thus the choice of the most appropriate design is not simple.
Methods: PubMed was searched to identify publications about the characteristics of different trial designs that can be
used in randomised, comparative small clinical trials. In addition, the contents tables from 11 journals were hand-
searched. An algorithm was developed using decision nodes based on the characteristics of the identified trial designs.
Results: We identified 75 publications that reported the characteristics of 12 randomised, comparative trial designs that
can be used in for the evaluation of therapies in orphan diseases. The main characteristics and the advantages and
limitations of these designs were summarised and used to develop an algorithm that may be used to help select an
appropriate design for a given clinical situation. We used examples from publications of given disease-treatment
-outcome situations, in which the investigators had used a particular trial design, to illustrate the use of the algorithm
for the identification of possible alternative designs.
Conclusions: The algorithm that we propose could be a useful tool for the choice of an appropriate trial design in the
development of orphan drugs for a given disease-treatment-outcome situation.Background
Small clinical trials are necessary when there are difficulties
in recruiting enough patients for conventional frequentist
statistical analyses to provide an appropriate answer. These
trials are often necessary for the study of rare diseases as
well as specific study populations e.g. paediatric, geriatric,
individually tailored therapies, regional subpopulations. In
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reproduction in any medium, provided the orThe European Medicines Agency guidelines on clinical tri-
als in small populations (CHMP/EWP/83561/2005) con-
siders the problems associated with clinical trials when
there are limited number of patients available to study and
clearly defines the field of application [1].
Rare diseases are defined on the basis of their low
prevalence, i.e. less than 1 in 2,000 people affected. It
has been estimated that there are between 6,000 and
8,000 rare diseases that may affect up to 30 million people
in the European Union alone, although these figures do
not come from published peer reviewed epidemiological
studies [2,3]. Only about 250 of these diseases have a code
in the existing International Classification of Diseases
(ICD) (10th version) [4]. Rare diseases cover a broadtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Cornu et al. Orphanet Journal of Rare Diseases 2013, 8:48 Page 2 of 12
http://www.ojrd.com/content/8/1/48diversity of diseases and patients, with about 50% of
those affected being children. About 80% of these rare
diseases have an identified genetic origin involving one
or several genes or chromosomal abnormalities [5]. The
others are caused by infections (bacterial or viral), or
allergies, or are due to degenerative, proliferative or
teratogenic (chemicals, radiations, etc.) causes. Some rare
diseases are also caused by a combination of genetic and
environmental factors [5]. Drugs (including orphan drugs)
are developed for treating these rare diseases, and their
efficacy and safety need to be evaluated but due to the
small number of potential trial participants, a standard
randomised controlled trial is often not feasible [6].
In children the issue is not restricted solely to rare
diseases as the difficulty in recruiting sufficient num-
bers of patients is a problem for even frequent diseases.
This difficulty is mainly due to ethical and psycho-
logical considerations, which not only represent an obs-
tacle to running clinical trials but also to protecting the
children. These considerations need to be taken into
account to design trials which minimise the risk for
individual patients (e.g. minimal numbers of samples
in pharmacokinetic/pharmacodynamic studies) as well
for the whole paediatric population [7]. Consequently,
the use of innovative methodologies enabling fewer
patients to be recruited could become the rule for dose-
finding and efficacy studies in the future.
Clinical trial methodology has evolved since the
mid-20th century so that now well-established and val-
idated methods are available for the design, conduct and
analysis of clinical trials [8]. It is generally accepted that an
appropriate trial design includes a sufficiently large sample
size and statistical power, and methods for minimising
bias to enable the results to be reliably interpreted. The
randomised, parallel-group controlled clinical trial de-
sign is generally considered as the gold standard, but in
some situations it is difficult to use this design. The type
of situation when it is not feasible includes rare diseases
with very low incidence/prevalence, individually tailored
therapies, and specific trial populations. The general re-
quirements for small trials are the same as those for
adequately sized trials, i.e. their design and analysis should
enable a reasonable measure of the treatment effect to be
obtained. The design should include an outcome that
can be measured to determine change or ‘success’, via a
baseline value and an ‘under-treatment’ value for the
outcome.
The minimisation of systematic bias remains funda-
mental, as for the more classical trial designs. These
biases include: selection bias, which is the biased alloca-
tion of patients to treatment or placebo groups; per-
formance bias, which is the unequal provision of care
apart from the treatment under evaluation; detection
bias, which is the biased assessment of the outcome;attrition bias, which is the biased occurrence and hand-
ling of deviations from protocol and loss-to-follow-up.
These biases can be minimised using validated method-
ology. Good-quality central randomisation can minimise
selection bias. Double-blind follow-up and outcome evalu-
ation can minimise the other biases, and when this is
not possible, the trial outcome should be measured in a
blinded manner, by someone who is not involved in the
patient’s care. Specific methods for the management of
missing data exist, e.g. replacement of missing measure-
ments in designs with intra-individual assessments, and
intention-to-treat analyses. A specific statistical analysis
plan is necessary for all trial designs, and should be
defined, a priori, in the trial protocol; the analysis plan
should be coherent with hypothesis tested and should
include appropriate control of the type I error rate [8].
There are a number of trial designs that have been
proposed as alternatives when the usual parallel group
designs are not appropriate or feasible [9]. Each of these
designs offers specific advantages, but they also have
specific limitations. Thus the choice of the most appro-
priate design is not simple. In addition, for any given
situation, several designs may be possible. We performed
a literature review of alternative trial designs and we
summarise their main characteristics in this paper and
present an algorithm that can be used to select the most
appropriate design(s) for given disease-drug-outcome
situations. To illustrate the use of the algorithm, we will
discuss case studies of published clinical trials, to ascer-
tain if alternative study designs could have been used.
Methods
PubMed was searched using combinations of the terms
given in Table 1 in the title field, with no limitations in
terms of language published up to end of 2010, to iden-
tify publications about the characteristics of different
trial design methods that can be used in randomised,
comparative small clinical trials, other than the standard
randomised controlled trial design. In addition, the ta-
bles of contents for 11 journals were hand-searched; the
years for each journal are indicated in Table 1.
The characteristics of the identified trial designs and
their advantages and disadvantages were summarised.
The assessment of advantages and limitations of each
design was based on the experience of the authors and
that of experts and academic opinions. Based on these
characteristics, we identified decision nodes, and then
developed an algorithm that can be used in practice to
select the most appropriate trial design.
Results
Results from literature search
A total of 1420 abstracts were identified. After screening
the titles and abstracts and obtaining full papers for
Table 1 Search strategy for the identification of articles
on the methods used for small clinical trials
Terms combined in PubMed search
• (“Rare diseases” OR “orphan*”) AND
(“Epidemiologic Methods” OR “Research Design” OR
“Clinical Trials as Topic”)
• Rare disease*
• Clinical trial*
• Clinical research
• Withdrawal
• Winner*
• Loser*
• Sequential
• Adaptive
• Delayed start
• Early escape
• N-of-1
• Randomi*
• Placebo phase
• Three stage
Journals (years) hand-searched:
• Statistics in Medicine (1990–2010)
• Orphanet Journal of Rare Diseases (2006–2010)
• Controlled Clinical Trials (2000–2004)
• Contemporary Clinical Trials (2005–2010)
• BMC Medical Research Methodology (2001–2011)
• Journal of Biopharmaceutical Statistics (1991–2012)
• Biometrical Journal (1990 – 2012)
• Statistica Sinica (1991–2012)
• Journal of Statistical Planning and Inference (1990 – 2012)
• Journal of the American Statistical Association (1990–2012)
• American Journal of Biostatistics (2010 – 2012)
* = truncation symbol used in PubMed search.
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that reported information about the methods for vari-
ous randomised, comparative trial designs that could
be used in for the evaluation of therapies in orphan
diseases.Summary and general characteristics of randomised,
comparative trial designs used in practice
The main characteristics and the advantages and limita-
tions of the 12 trial designs (adaptive randomization
designs were grouped in one single category) that were
identified are summarised in Figure 1 and Table 2 [10-24].
Some examples of trials using the different designs are
given in Table 3 [12,25-49].Parallel group design
In a parallel group design trial, individuals are random-
ized to receive the tested treatment or control. This is
the most commonly used design, which is possible in al-
most any situation, but requires larger sample sizes than
other designs [24].Factorial design
With the 2 × 2 factorial design trial, participants are ran-
domized to treatment A or corresponding placebo to
test one hypothesis, and randomized again within each
group to treatment B or corresponding placebo to test a
second hypothesis, thus enabling two different hypoth-
eses to be tested simultaneously. This design is based on
the parallel group design. It also requires that there is no
interaction between treatments A and B. If interaction
exists, then loss of power is possible in case of separate
analyses of the four different combinations. This design
enables the measurement of an effect or an interaction
which otherwise might not be apparent.Cross-over design, Latin square, N-of-1
Each participant in a cross-over trial receives two treat-
ments in a random order and acts as their own control.
Latin-square design differs from cross-over design in
terms of the number of studied treatments; latin-square
design is used when more than two treatments are com-
pared in the same trial. For example when three treat-
ments are considered in the trial, the corresponding
latin-square involves three treatment periods and two
wash-out periods occurring between each treatment
period for each of the three groups of patients.
N of 1 trials or single-subject designs are defined as time-
series designs in which an intervention is evaluated in one
single patient. A typical single patient trial consists of ex-
perimental/control treatment periods repeated a number of
times. The order of treatment is randomly assigned within
each treatment period pair. Formally, this design is
known as a structured within-patient randomized con-
trolled multi-crossover trial design. Usually, the pri-
mary objective of such a trial is to determine the
treatment preference for the individual patient.
For cross-over trials, as for all intra-patient designs,
the disease must be stable, and the patient’s health status
must be identical at the beginning of each treatment
period. There can be a carry-over effect, if the treatment
effect from the previous period is still present during the
following period. To avoid this, a wash out period is
generally added between each treatment period of the
trial. The duration of follow-up for the patient is therefore
longer than for a parallel design, and there is a risk that a
significant number of patients do not complete the study.
A: parallel groups
B: cross-over C: factorial
D: N-of-1
E: randomised placebo phase F: stepped wedge G: randomised withdrawal
Figure 1 Schematic representation of some randomised clinical trial designs.
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In this design an initial randomised placebo controlled
phase is followed by a phase during which all patients re-
ceive the active treatment. This design can be used to as-
sess disease progression as well as disease relapses (or
other short term outcomes). This trial design requires that
the treatment periods are sufficiently long for a thera-
peutic effect to be obtained, that as few as possible pa-
tients are lost-to-follow-up (and if possible, the same
number in both groups) and that there are a sufficient
number of follow-up visits to measure the treatment effect
to allow a precise estimation of the treatment effect slope.
The limitations of this design include the fact double-
blinding is only really present in the first trial period, since
with this design in the second period all the patients re-
ceive active treatment. In addition, the evolution of the
symptoms during the follow-up can enable the treatment
group for the previous period to be identified. This can in-
duce an evaluation bias. A carry-over effect from the first
to the second period cannot be excluded, as well as a
training effect if the primary criterion is a score. Hence,
this type of trial is almost always explicative (i.e. evaluates
the effect of the treatment on the symptoms and the evo-
lution of the disease), losing all its pragmatic repercus-
sions, unlike, for example, a classical parallel group trial
with a follow-up equivalent to the two periods in the de-
layed start design.
Minimising time on inactive treatment or placebo:
randomised withdrawal, early escape, randomised
placebo phase, stepped wedge designs
With the randomised withdrawal design, all eligible pa-
tients with the disease being studied receive open-labeltreatment for a specified period to identify a subgroup of
patients who can successfully achieve a pre-defined level
of response. The patients in this subgroup are then ran-
domized to continue the tested treatment or to receive a
placebo in a double-blind fashion. The randomised with-
drawal design aims to evaluate the optimal duration of a
treatment in patients who respond to the treatment. In
the randomised early escape design, for the patients who
do not respond to therapy, time on ineffective treatment
is minimised. Both these designs are combined in the
three-stage randomised trial design. In the other possible
designs (randomised placebo phase, stepped wedge trials)
the time spent on placebo is minimised, and all patients
receive the active treatment at the end.
Adaptive randomisation (play the winner, drop the looser
designs)
The play-the-winner and the drop-the-loser designs aim
to favour the group with the best chance of success by
increasing the probability of patients being randomised
to that group. For adaptive randomization designs, the
procedure is best described by using the urn model
which is common in the statistical literature; in the urn
there are various types of balls representing particular
treatments; patients accrue sequentially and at each
stage, the probability of allocating a particular treatment
to a given patient depends on the number of various
types of balls in the urn. The response of each patient
after treatment plays an essential role in the determin-
ation of subsequent compositions of balls in the urn.
In the randomized play the winner (PW) procedure,
the basic strategy is to ‘reward’ more balls to successful
treatments. The urn contains K different types of balls,
Table 2 Summary of the characteristics of the various randomised, comparative trial designs (it is assumed for all designs that the control group is a placebo)
Study design Main characteristics Randomisation Main advantages Main disadvantages
Parallel groups
(comparison
between
groups) [24]
Patients are assigned to a treatment
group for the duration of the trial.
Randomisation to one of two or more
treatment groups, with a pre-specified
randomisation ratio.
Design simple to understand and to
implement.
Larger sample size often required, compared
with other designs.
Treatment groups can have different
numbers of patients.
Difficulties with recruitment possible, if
placebo-controlled.
Analysis and interpretation of results
is simple.
Cannot estimate the contribution of inter- and
intra-patient variability to the overall variability.
Factorial Can answer two or more questions
with one trial
Patients are randomised twice, once for
treatment A or placebo and then for
treatment B or placebo
Time-saving for the trial sponsor Need to be sure that there is no interaction
between treatments A and B
Requires fewer patients to obtain the
answer to two or more questions
Cross-over Patient receives both of two treatments,
A and B, in a pre-specified sequence.
Patients act as their own control.
Randomisation to a pre-specified
treatment sequence.
Smaller sample size than parallel
groups.
Stable chronic diseases (assumes patient’s
state is comparable at the start of both
periods of treatment).Endpoint must not be
sensitive to learning processes.Requires a
wash-out period between treatment periods.
Follow-up is at least twice as long compared
with corresponding parallel group trials. The
analysis must confirm the absence of
treatment - period interaction
Results depending only on within-
patient variability.
Often used in healthy volunteers (for
phase 1 clinical trials)
Latin square More than two treatments to compare Randomisation to a pre-specified
treatment sequence.
Same as for cross-over design. Same as for cross-over design, except carry-
over is controlled (similar properties as those
for Latin square design).Balanced design, i.e. every treatment
(or dose) appears only once in each
sequence and each treatment period.
N-of-1
[14,19,23]
Only one patient and design aims to
assess effects of several treatments
in one individual
The order of treatment(s) and placebo
periods are randomly assigned for the patient
Provides an estimate of individual
effectiveness (personalized medicine)
Same as for cross-over design. Needs a stable,
chronic disease
Patients are more likely to have better
adherence to treatment, and
understand their disease and
treatment better
Delayed start
[10,12,16]
Two phases: initial placebo controlled phase
(patients randomised to treatment or
placebo) followed by active control phase
(all patients receive treatment) – those in
the initial placebo group have a delayed
start
In first phase, patients randomised to early
start group (treatment) or delayed start group
(placebo)
Allows more patients to receive active
treatment
At the start of the second phase, the patients
are not comparable. No real blinding for the
second period; carry over effect possible.
Can distinguish effects on symptoms
and effects on the disease evolution
Randomized
placebo-phase
[13]
All patients receive the tested treatment in
the end – but have varying lengths of time
on placebo.
Randomisation of time from enrolment to
starting tested treatment
Can be used for disease-modifying
therapies, in diseases with a rapid,
unfavourable evolution. All patients
receive active treatment
Variable length of placebo period reduces
statistical power
Assumes that a response will occur
sometime after an effective treatment is
given, so that patients who start the
treatment earlier should, on average,
respond sooner
Low and intermediate potency therapies show
large variability for response
Limited ability to estimate size of treatment
effect
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Table 2 Summary of the characteristics of the various randomised, comparative trial designs (it is assumed for all designs that the control group is a placebo)
(Continued)
Stepped
wedge [11]
All patients receive tested treatment in the
end. Intervention allocated sequentially to
participants (either as individuals or clusters
of individuals)
For a 5-step wedge design, all patients start
with control then for the following five time
periods individual or clusters randomised to
treatment to finish in the last period with all
patients receiving tested treatment
Useful when there is a prior belief
that treatment will do more good
than harm
There might be a risk of contamination
between intervention participants, and a need
for blind assessment of outcome
Also, when an innovation cannot be
delivered concurrently to all units
Randomised
withdrawal
Used to assess treatment continuation in
patients who are responding to the
treatment.
Randomisation of responders to continue
treatment or switch to placebo
Reduces the time on placebo since
only responders are randomised to
placebo.
For use in chronic diseases, Not suitable for
unpredictable diseases (e.g. spontaneous
remission) or those with slow evolution. The
treatment effect is overestimated since only
responders are included (and compared to
placebo)
All patients initially receive the tested
treatment; responders are randomised to
continue treatment or to receive placebo
Can assess if treatment needs to be
continued or can be stopped
Possible carry-over effect for adverse effects.
Early escape Patients withdrawn if they satisfy a priori
failure criterion
Randomisation to active treatment or placebo Reduces the time on placebo or in
treatment failure.
Difficult to define a binary failure/success
outcome.
Analyse failure rate, so minimises
exposure to ineffective treatment
Only short-term efficacy evaluated.
Loss of power if significant number of patients
‘escape’
Three-stage[15] Initial randomised placebo-control phase, a
randomised withdrawal stage for
responders, and a third randomised phase
for placebo non-responders who
subsequently respond to treatment
Randomisation to treatment or placebo and
randomised withdrawal for responders
Three separate (independent)
assessments of efficacy which are
then combined (Fisher’s method) to
derive a single overall p-value.
Applicable only to chronic conditions where
both response to therapy and withdrawal of
therapy can be assessed.
Care should be taken to allow the withdrawal
phase to be sufficiently long so that the drug
can be completely washed out and the
clinical effects of therapy reversed.
Subjects may barely meet criteria for being a
responder and would consequently forgo
active treatment even though they may have
benefited from it.
Since fewer patients may be available in the
initial stage of the trial, the ability to precisely
determine initial response rates may be less
than with a traditional randomized trial
design.
May be less suited for controlled assessment
of safety
Fewer patients required compared
with parallel group design.
Reduces the time on placebo or non-
efficacious treatment.
May evaluate the efficacy of a
therapeutic agent in a particular
patient subpopulation when efficacy
in the general patient population has
already been established.
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Table 2 Summary of the characteristics of the various randomised, comparative trial designs (it is assumed for all designs that the control group is a placebo)
(Continued)
Adaptive
randomization
designs -play
the winner
[17,20]
An adaptive randomization design. The probability of being randomised to one
group is modified according to the results
obtained with previous patients. It favours the
group with favourable results (play the
winner), or penalise the group with
unfavourable results (drop the looser); it can
be generalised to multi-treatment clinical
trials, and delayed responses (Generalized
drop the looser)
Reduces the number of patients
receiving a less effective treatment.
Unequal sample size reduces power.
Need to have binary outcome, (success/
failure)
In some situations, the number of patients
who have actually received one of the
treatments is very low.
Could improve patient recruitment
due to better satisfaction
-drop the
losers [18]
-generalised
drop the loser
[21,22]
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Table 3 Examples of clinical trials that have used the different designs
Study design Examples
Parallel groups • Phosphodiesterase-5 inhibition for pulmonary hypertension in heart failure [31]
• Vigabatrin in infantile spasms due to tuberous sclerosis (comparative parallel design) [27]
• Stiripentol in Dravet syndrome (placebo controlled parallel design) [28]
Factorial • Aspirin and simvastatin for pulmonary arterial hypertension [35]
Cross-over • Amantadine in Huntington disease [40]
• Oral sildenafil therapy in severe pulmonary artery hypertension [45]
• Sirolimus therapy to halt the progression of ADPKD [42]
Latin square • Plasma exchange for induction and cyclosporine A for maintaining remission in Wegener’s granulomatosis [47]
• Assessment of disease flare in patients with systematic lupus erythematosus [33]
N-of-1 • Amitriptyline in fibromyalgia [34]
• Tramadol to treat chronic cough [37]
• L-arginine in ornithine transcarbamylase deficiency carrier [32]
Delayed start • Rasagiline in Parkinson’s Disease [16,41]
Randomised placebo-phase • Low dose phenelzine in the chronic fatigue syndrome [39]
Stepped wedge • Long-term efficacy of HBV vaccine to prevent liver cancer and chronic liver disease [49]
• School-based anti-smoking campaign, (delivered by one team of facilitators who travel to each school)
• Sure Start programme in the UK (http://www.ness.bbk.ac.uk)
Randomised withdrawal • Withdrawal of hydroxychloroquine sulfate in systemic lupus erythematosus [48]
• Etanercept in children with polyarticular juvenile rheumatoid arthritis [38]
• Vigabatrin withdrawal randomized study in children with epilepsy [26]
• Antipsychotic withdrawal with Alzheimer’s Disease [25]
• Stiripentol withdrawal design in children with partial epilepsy [29]
Early escape • Intravenously golimumab in patients with active rheumatoid arthritis [36]
• Pain control for post-operative pain [46]
Three-stage • Etanercept in children with polyarticular juvenile rheumatoid arthritis [15,38]
Adaptive randomisation • Prevention of postoperative venous thromboembolism in digestive surgery [43,44]
• Reduction of maternal-infant transmission of Human Immunodeficiency Virus Type 1 with zidovudine [30]
• No example found for the ‘drop the loser’ design
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arrives, a ball is drawn at random with replacement. If
it is a type i ball, the patient receives treatment i. A
successful response to the treatment results in the addition
of a type i ball to the urn. If the response is a failure, a
different ball is added to the urn, this ball being partitioned
according to the existing proportion of balls for other treat-
ments in the urn.
In the drop the loser (DL) procedure, instead of adding
balls to reward successes, balls are removed when fail-
ures are observed. In the urn, besides treatment balls,
there are immigration balls. When an immigration ball
is selected, balls for all types will be added (except immi-
gration), preventing the total elimination of any type of
treatment balls. The DL rule was reported to have small
variability in terms of treatment attribution and high
statistical power and has been shown to yield satisfactory
results in terms of reducing the number of failures.Nevertheless, adaptive randomization has some limita-
tions, i.e. a lack of clear methodology to cope with delayed
test responses which are common in clinical studies
and its application is limited to clinical trials with bin-
ary responses.Decision nodes
The decision nodes were empirically derived from the
requirements and limitations of each specific design as
well as from their advantages. We identified the design
characteristics that seemed most likely to guide the choice
of a specific design:
 reversible or irreversible outcomes
 fast (defined as up to a few weeks) or slow response
to treatment
 possibility of minimising the time on placebo
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by the end of the trial
 possibility of performing intra-patient or inter-
patient comparisons.
Algorithm development and testing
These decision nodes were used to design the algorithm
(Figure 2). To test this algorithm, we took some exam-
ples of clinical trials that used one of these designs and
worked through the decision nodes to see what alterna-
tive designs would have been possible.
Case study 1
The first example involves an n-of-1 trial that assessed
the efficacy of L-arginine vs placebo in a patient with
ornithine transcarbamylase deficiency (OTCD) [32].
Female carriers of this autosomal genetic disorder may
be asymptomatic, or have symptoms ranging from protein
aversion only, to profound neurological impairment and
death due to secondary encephalopathy. Arginine supple-
mentation is required, but it is not certain if mildly symp-
tomatic females will benefit from this treatment. An
n-of-1 trial in a mildly symptomatic woman with alterna-
tive weeks of placebo and L-arginine was performed. The
patient’s symptoms were measured on days 5 and 6 of
each weekly period; three treatment pairs of L-arginine
and placebo, each with two measurements, were used to
minimise bias. The results showed consistently higher
scores for L-arginine than for placebo. The outcome in
this example is reversible, and the response is rapid so,
using the algorithm, all designs would be possible (left-
hand side of the decision tree). At the third decision node,
if it was decided to minimise time on placebo, seven dif-
ferent designs would remain possible. Since this treatment
is intended as a long-term treatment, and in view of the
encouraging results from this n-of-1 trial, larger scale trials
could be designed to ensure that all patients received
active treatment by the end of the trial; in this context,
delayed start, randomised placebo phase and stepped
wedge designs could be considered.Case study 2
Another example that was used to test the algorithm was
a randomized, blinded withdrawal trial of intravenous
immunoglobulin in patients with polyarticular juvenile
rheumatoid arthritis resistant to other treatments [50].
The outcome was ‘clinically important improvement’, which
is reversible, but relatively slow (>3 months). If the investi-
gators had wanted to minimise time on placebo, they could
have used the delayed start, randomised placebo phase or
stepped wedge designs. The randomized withdrawal design
is suitable for a chronic disease. In this example, the au-
thors justified the choice of trial design on the grounds ofethics; reducing the time on placebo (and preventing long-
term harmful effects due to worsening of the disease).
Case study 3
A trial with a play-the-winner design assessed the effi-
cacy of enoxaparin given before or after digestive surgery
to prevent venous thromboembolism [51]. In this trial,
the outcome, venous thromboembolism, is irreversible
and the response under treatment is rapid. In addition,
both groups received active treatments, since the time of
treatment start, before or after surgery, was randomised.
In the algorithm, we can see that four other trial designs
could have been used. However, in this context, some of
the designs would not be possible; e.g. randomised pla-
cebo phase, and stepped wedge. Using a parallel group
or factorial trial design for simultaneous comparison of
two treatments with each of their controls (provided
there is no interaction) would have been possible.
Case study 4
The final example is a trial with a delayed start design
to assess a potentially disease-modifying neuro-protective
drug, rasagiline in patients with Parkinson’s disease [16].
The primary endpoint was based on the Unified Parkinson’s
Disease Rating Scale (UPDRS; a 176-point scale with higher
numbers indicating more severe disease); this outcome
is reversible and the response can be considered to be
slow. Possible designs are: randomised placebo phase,
stepped wedge design, both of which would have also
minimised time on placebo and ensured that all patients
received active treatment in the end. However, the se-
lected design is the only one able to measure the treat-
ment effect on the symptoms and the evolution of the
disease. Three hypotheses had to be tested (sequen-
tially), in order to conclude that the treatment was
efficacious in this trial:
1. the superiority of the treatment over placebo: first
period, between weeks 12 and 36;
2. the superiority of the early start over the deferred
start (comparison of the difference in effect over the
combined periods 1 and 2, week 72 vs. baseline; and
3. the non-inferiority of early vs. deferred start
(comparison of the effect slopes in the second
period, between weeks 48 and 72.
Discussion
In this review of alternative clinical trial designs for the
evaluation of interventions in the setting of rare diseases
we have identified 12 possible designs. Based on the
characteristics of these trial designs we have developed
an algorithm and have illustrated its use through exam-
ples of published trials. These examples show that alter-
native designs to those used in the publications would
Figure 2 Schematic representation of trial design algorithm.
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trial, number of patients needed, length of trial, and
how the variability is handled, could be important in
the choice of the most suitable trial design. A recently
published review provided an algorithm with six alter-
native designs [52]. Although this seems to be a simpler
approach to decision-making than our approach, our
algorithm includes 12 alternative designs, all of them
being randomised designs.
One limitation to our algorithm is that we have arbi-
trarily selected decision nodes to go through the algo-
rithm but other nodes are possible, for example, stable
disease or not. These proposed decision nodes were
selected based on the experience of two of the authors
(CC and PN) and are not based on objective criteria.
This proposition can be debated by the scientific
community and will need to be tested before it can
be validated.
In this paper, we addressed the design of a small pivotal
trial where one experimental treatment is compared with
a control. We did not address the design of clinical
programmes for rare diseases, seamless approaches whichcan combine dose selection and confirmation in the
same trial, or dose (and regimen) finding trials [53-55].
Other approaches, that we can call ‘meta-methods’ or
‘orthogonal methods’ can minimise the number of patients
needed if applied to some of the ‘basic’ designs considered
in our algorithm. For example, meta-analyses of clinical
trials, including prospective meta-analyses, Bayesian infer-
ential methods, statistical techniques such as sequential
analyses (e.g. triangular tests) and sample size reassess-
ment methods could contribute to minimise the sample
size. However, the fact that sample size reassessment could
contribute to minimize the sample size is theoretical, as
common practice is to use sample size reassessment to
increase rather than decrease sample size (but when
used with group sequential boundaries, the design as a
whole can contribute to diminish the sample size).
Based on the algorithm that was developed we can see
for any given disease-outcome situation that there is
generally more than one design that could be used. Other
factors could be incorporated into the selection of the
most appropriate design, such as statistical power, trial
duration for patients, investigators and trial sponsors,
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stage in the decision process will require building models
of the pair: disease-treatment that be used to simulate
the results from each design before selecting the best
design for the specific research question. This approach
will be developed in the setting of the CRESim project
(Rare disease: use of clinical trial simulation for the
choice and optimisation of study design), funded by
the European Commission PRIOMEDCHILD ERA-NET
Programme [56]. One deliverable from this project will be
the development of a web-based platform for performing
in silico experiments to assess different designs for drug
evaluation in children with rare diseases. The algorithm
could also be useful in other settings, such as specific
small sub-populations of common diseases and in settings
where recruitment is likely to be very difficult.
Conclusions
The algorithm that we propose seems to be a useful tool
in the case of rare diseases and the development of
orphan drugs as well as for specific populations where
recruitment could be difficult. Use of this algorithm will
facilitate the choice of the most appropriate design for
a given disease-treatment-outcome situation.
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